Clovis gets approval for Rubraca from European Commission

BOULDER — Clovis Oncology Inc. (Nasdaq: CLVS) has had its drug Rubraca, also known as rucaparib, authorized by the European Commission for use as a monotherapy treatment for adults with certain types of ovarian, fallopian tube or primary peritoneal cancers.

“Rucaparib provides a unique opportunity within Europe for women with BRCA mutated ovarian cancer, for whom platinum chemotherapy isn’t an option, to receive an oral non-chemotherapy treatment,” Dr. Rebecca Kristeleit, clinical senior lecturer and consultant medical oncologist at University College London in the U.K, said in a prepared statement. “In this group of patients with limited treatment options, rucaparib provides a much-needed oral targeted…